Sermorelin for Growth Hormone Deficiency

Sermorelin

8.0 cm/yr

Mean height velocity in GH-deficient children after 6 months of daily sermorelin, up from 4.1 cm/yr at baseline, in a 110-patient multicenter trial.

Thorner et al., J Clin Endocrinol Metab, 1996

Thorner et al., J Clin Endocrinol Metab, 1996

View as image

Sermorelin is a 29-amino-acid synthetic peptide that represents the biologically active fragment of growth hormone-releasing hormone (GHRH). The full GHRH molecule is 44 amino acids long, but only the first 29 are required for full receptor binding and signal transduction. This shorter version, GHRH(1-29)-NH2, was developed as a diagnostic and therapeutic agent for growth hormone deficiency (GHD) and received FDA approval in 1997. It was commercially discontinued in 2008 for business reasons, not safety concerns. This article is part of the sermorelin cluster covering the peptide's evidence base, mechanisms, and clinical context.

What Sermorelin Is and How It Differs from GH

Sermorelin does not contain growth hormone. It stimulates the pituitary gland to produce and release its own GH by mimicking the signal that the hypothalamus normally sends. This distinction shapes its entire clinical profile.

When a patient receives exogenous recombinant human growth hormone (rhGH), the pituitary's own GH production shuts down through negative feedback. The body receives a flat, continuous dose that does not replicate the natural pulsatile pattern of GH secretion. With sermorelin, the pituitary still responds to somatostatin (the inhibitory hormone), so GH release occurs in pulses and cannot easily exceed physiologic levels.^[1]

A 1999 review by Prakash and Goa documented that sermorelin's primary advantage is this built-in safety mechanism. Because somatostatin feedback remains intact, the risk of GH excess (acromegaly-like side effects, insulin resistance, fluid retention) is lower than with direct GH injection.^[1] The tradeoff: sermorelin only works if the pituitary still has functional somatotroph cells capable of responding. In patients with pituitary destruction or severe pituitary disease, sermorelin cannot stimulate what no longer exists.

For comparison with next-generation GHRH analogs that address sermorelin's short half-life, see the CJC-1295 overview.

Pediatric Growth Hormone Deficiency: The Core Evidence

Sermorelin's strongest clinical data comes from pediatric trials. The Geref International Study Group conducted a multicenter, open-label study of 110 previously untreated prepubertal children with GH deficiency. Children received 30 mcg/kg of GHRH(1-29) subcutaneously at bedtime daily for up to one year.^[2]

Of the 86 patients eligible for efficacy analysis, mean height velocity increased from 4.1 cm/yr at baseline to 8.0 cm/yr after 6 months and 7.2 cm/yr after 12 months. The slight decline from month 6 to 12 is consistent with the natural deceleration seen with most GH-axis therapies. The treatment was well tolerated: transient facial flushing and injection site pain were the most common adverse events.

A head-to-head comparison added useful context. Chen et al. (1993) randomized 60 children with proven hypothalamic-origin GH deficiency into three groups: GHRH(1-29) at 30 mcg/kg/day, GHRH(1-29) at 60 mcg/kg/day, or recombinant GH at 0.1 IU/kg/day for 6 months.^[3] No significant difference was found between the two GHRH doses, suggesting a ceiling effect for dose-response. The GH group grew somewhat faster, but the GHRH group demonstrated that pituitary stimulation could produce clinically meaningful growth acceleration without exogenous hormone.

Kirk et al. (1994) extended this work to 18 children with idiopathic short stature (height below normal but without classic GH deficiency). These children had normal GH responses to provocative testing (peak GH above 20 mU/L), yet still grew slowly. After 12 months of GHRH(1-29) treatment, growth velocity increased significantly and the improvement was sustained throughout the treatment period.^[4] This suggested that sermorelin could benefit children on the milder end of the GH insufficiency spectrum, not just those with clear-cut biochemical deficiency, and that some short stature may involve subtle GHRH signaling deficits that standard testing does not capture.

Adult Applications: The Age-Related Decline

GH secretion declines with age at a rate of roughly 14% per decade after age 30. By age 60, many adults have GH and IGF-1 levels that overlap with those seen in younger adults with diagnosed GH deficiency. Whether this age-related decline constitutes a treatable condition remains debated, but several trials have tested GHRH analogs in older adults.

Khorram et al. (1997) conducted a single-blind, randomized, placebo-controlled trial in 10 women and 9 men aged 55 to 71. Participants self-injected a GHRH(1-29) analog ([Nle27]GHRH(1-29)-NH2, chemically identical to sermorelin except for one amino acid substitution to improve stability) at 10 mcg/kg nightly for 16 weeks after a 4-week placebo run-in.^[5]

The results showed:

• IGF-1 levels increased significantly within 2 weeks and remained elevated for 12 weeks
• IGFBP-3 (the main binding protein that extends IGF-1's half-life) also increased
• Skin thickness increased in both men and women
• Lean body mass increased in men only
• No significant changes in bone mineral density or fat mass in either gender

The study was small (19 subjects), short (16 weeks), and single-blind rather than double-blind. The sex-specific lean mass effect has not been replicated in a larger trial. These are meaningful limitations.

A more recent observation comes from Sigalos and Pastuszak (2017), who retrospectively reviewed 14 hypogonadal men (mean age 33.2 years) prescribed a combination of GHRP-6, GHRP-2, and sermorelin (100 mcg each, three times daily) for a mean of 134 days. Mean IGF-1 rose from 159.5 to 239.0 ng/mL.^[6] The combination makes it impossible to attribute the IGF-1 increase specifically to sermorelin versus the GHRPs, but the study reflects how sermorelin is used in current clinical practice: often combined with growth hormone releasing peptides that work through the ghrelin receptor rather than the GHRH receptor.

The Sleep Connection

GH is released primarily during slow-wave sleep (deep sleep), making the timing of sermorelin administration clinically relevant. Marshall et al. (1996) tested whether the pattern of GHRH delivery affected sleep architecture in healthy young men.^[7]

Episodic GHRH administration (pulsed delivery) promoted slow-wave sleep more effectively than continuous infusion. This finding has practical implications: bedtime dosing of sermorelin may enhance the natural GH pulse that occurs during the first sleep cycle, producing both GH release and improved sleep quality simultaneously. The relationship between MK-677 and sleep architecture shows a similar pattern across different GH secretagogue classes.

Why Sermorelin Was Discontinued

Sermorelin (marketed as Geref) received FDA approval in 1997 and was commercially available until 2008. EMD Serono, the manufacturer, discontinued production for commercial reasons. The decision was not driven by safety signals, efficacy concerns, or regulatory action.

The competitive landscape explains the withdrawal. Recombinant GH (Genotropin, Humatrope, Norditropin, and others) dominated the pediatric GHD market with stronger efficacy data. Sermorelin produced slightly lower growth rates than direct GH in the head-to-head trial,^[3] making it a harder sell to endocrinologists who already had effective options. The drug's niche advantage, a better safety profile through physiologic feedback, was not enough to sustain commercial viability.

After discontinuation, sermorelin became available through compounding pharmacies under Section 503A of the Food, Drug, and Cosmetic Act. Compounded sermorelin is not FDA-approved, but it is legally prescribed by physicians. Quality, purity, and potency standards vary between compounding pharmacies.

Sermorelin vs CJC-1295: The Half-Life Problem

Sermorelin's major pharmacokinetic limitation is its short half-life, estimated at 10 to 20 minutes after subcutaneous injection. This means the pituitary receives a brief GHRH signal, releases a GH pulse, and then the stimulus disappears. To maintain elevated GH/IGF-1 levels, daily injections are required.

CJC-1295, a modified GHRH analog, was designed to solve this problem. Alba et al. (2006) showed that CJC-1295 administered once daily normalized growth in GHRH knockout mice, demonstrating that a long-acting GHRH analog could replace the need for frequent dosing.^[8] CJC-1295 with Drug Affinity Complex (DAC) extends the half-life to several days by binding to serum albumin. The tradeoff is that prolonged GHRH stimulation may blunt pulsatility, which is the very feature that makes sermorelin's approach physiologic. For a detailed breakdown, see CJC-1295 with DAC vs without DAC.

Mod GRF(1-29), also known as CJC-1295 without DAC, is essentially a modified sermorelin with amino acid substitutions at positions 2, 8, 15, and 27 to resist enzymatic degradation. It retains a short half-life (30 minutes vs sermorelin's 10-20 minutes) while being more resistant to dipeptidyl peptidase-IV cleavage.

What the Evidence Does Not Show

Several claims commonly made about sermorelin lack adequate supporting data.

Fat loss. The Khorram trial did not find significant fat mass reduction in either men or women after 16 weeks. Individual compounding pharmacy marketing often cites fat loss as a benefit, but the controlled evidence does not support this claim at the doses and durations studied.

Muscle gain beyond lean mass. The lean body mass increase observed by Khorram was modest, male-only, and measured by DXA rather than functional outcomes. Whether this translates to improved strength, exercise capacity, or daily function was not assessed.

Anti-aging. No randomized controlled trial has demonstrated that sermorelin reverses or slows aging in any measurable biomarker panel. The age-related decline in GH is well documented, and restoring IGF-1 levels to those of younger adults is achievable, but whether doing so produces net clinical benefit (rather than just higher lab values) remains unproven.

Dose optimization. The 30 mcg/kg bedtime dose used in pediatric trials became the reference standard largely by convention. Systematic dose-ranging studies in adults have not been published. The Chen et al. trial found no difference between 30 and 60 mcg/kg, suggesting higher doses may not produce proportionally better results.^[3] Current compounding pharmacy doses (ranging from 100 mcg to 500 mcg nightly) are based on clinical experience rather than controlled evidence, and the optimal dose for specific adult outcomes remains unknown. For a broader view of growth hormone deficiency diagnosis and treatment, the evidence gaps extend well beyond sermorelin.

Current Regulatory and Clinical Status

Sermorelin occupies an unusual regulatory position. It was once FDA-approved, is no longer commercially manufactured, but remains legally available through compounding pharmacies. It is not a controlled substance. The sermorelin vs recombinant GH comparison and the broader anti-aging evidence are covered in dedicated articles within this cluster.

In clinical practice, sermorelin is most commonly prescribed by anti-aging and functional medicine clinicians for adults with low IGF-1 levels, often in combination with GHRPs like ipamorelin or GHRP-2. This combined approach targets both the GHRH receptor (via sermorelin) and the ghrelin receptor (via GHRPs) simultaneously, theoretically producing a synergistic GH release. The tesamorelin profile covers the only GHRH analog that remains FDA-approved (for HIV-associated lipodystrophy).

The Bottom Line

Sermorelin, the 29-amino-acid active fragment of GHRH, nearly doubled growth velocity in a 110-patient pediatric trial and raised IGF-1 in older adults in a small 19-subject study. Its physiologic advantage over exogenous GH is preserved feedback regulation through somatostatin. Its clinical disadvantage is a short half-life requiring daily injection and slightly lower growth rates compared to direct GH therapy. Discontinued commercially in 2008 for business reasons, sermorelin remains available through compounding pharmacies.

Frequently Asked Questions

What is sermorelin used for?

Sermorelin was originally FDA-approved in 1997 for diagnosing and treating growth hormone deficiency in children. In a 110-patient trial, daily subcutaneous sermorelin (30 mcg/kg at bedtime) increased growth velocity from 4.1 to 8.0 cm/yr over 6 months (Thorner et al., 1996). It is now primarily used off-label through compounding pharmacies for adults with low IGF-1 levels.

Is sermorelin the same as growth hormone?

No. Sermorelin stimulates the pituitary to release its own growth hormone, while recombinant GH (Genotropin, Norditropin) delivers the hormone directly. The key difference is that sermorelin preserves the body's somatostatin feedback system, making supraphysiologic GH levels difficult to achieve (Prakash and Goa, 1999). Direct GH injection bypasses this feedback.

Why was sermorelin discontinued?

EMD Serono discontinued commercial production of sermorelin (Geref) in 2008 for business reasons, not safety concerns. Recombinant GH products dominated the market with stronger efficacy data. Sermorelin remains legally available through compounding pharmacies and is not a controlled substance.

Does sermorelin increase IGF-1?

Yes. In a controlled trial of 19 adults aged 55-71, a GHRH(1-29) analog raised IGF-1 levels within 2 weeks of nightly injections, with elevations sustained for at least 12 weeks (Khorram et al., 1997). A retrospective study of 14 men showed IGF-1 increased from 159.5 to 239.0 ng/mL over 134 days when sermorelin was combined with GHRPs (Sigalos and Pastuszak, 2017).

What is the difference between sermorelin and CJC-1295?

Both are GHRH analogs that stimulate pituitary GH release, but they differ in half-life. Sermorelin lasts 10-20 minutes after injection, requiring daily dosing. CJC-1295 with DAC lasts several days by binding serum albumin. Mod GRF(1-29), or CJC-1295 without DAC, is a modified sermorelin with a 30-minute half-life and greater enzymatic stability (Alba et al., 2006).

What are sermorelin side effects?

In the 110-patient Geref International Study Group trial, the most common adverse events were transient facial flushing and pain at the injection site (Thorner et al., 1996). No serious adverse events were attributed to sermorelin in any published trial. The somatostatin feedback mechanism limits the risk of GH excess, but long-term safety data in adults using compounded sermorelin is limited.